Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved ...
Phase 3 trial data showed the pozelimab and cemdisiran (poze-cemdi) combination achieved greater control of intravascular hemolysis in PNH patients compared to ravulizumab, with 96% achieving adequate LDH control versus 80% with ravulizumab. Poze-cemdi also demonstrated complete, uninterrupted inhibition of terminal complement, offering potential for less frequent, subcutaneous administration.
Reference News
Phase 3 trial data showed the pozelimab and cemdisiran (poze-cemdi) combination achieved greater control of intravascular hemolysis in PNH patients compared to ravulizumab, with 96% achieving adequate LDH control versus 80% with ravulizumab. Poze-cemdi also demonstrated complete, uninterrupted inhibition of terminal complement, offering potential for less frequent, subcutaneous administration.